NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

BNTX

BioNTech SE ADR

Jun 30 • 04:00PM ET

106.47

Dollar change -0.25
Percentage change -0.23	%

Healthcare • Biotechnology • Germany • NASD

Peers: MRNA PFE NVAX AZN JNJ GSK BMY GILD LLY SNY

| Held by: IBB FBT FNDF BBH TCAF SPDW IDNA QQQJ BBEU BBIN

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-3.44	Insider Own	1.53%	Shs Outstand	240.39M	Perf Week	3.36%
Market Cap	25.59B	Forward P/E	-	EPS next Y	-5.86	Insider Trans	0.00%	Shs Float	236.71M	Perf Month	6.20%
Enterprise Value	11.07B	PEG	-	EPS next Q	-2.07	Inst Own	21.15%	Short Float	2.58%	Perf Quarter	12.13%
Income	-812.81M	P/S	8.62	EPS this Y	-71.23%	Inst Trans	1.92%	Short Ratio	5.04	Perf Half Y	-6.71%
Sales	2.97B	P/B	1.25	EPS next Y	-4.75%	ROA	-3.46%	Short Interest	6.11M	Perf YTD	-6.56%
Book/sh	85.05	P/C	1.72	EPS next 5Y	-20.92%	ROE	-3.87%	52W High	131.49 -19.03%	Perf Year	29.02%
Cash/sh	61.74	P/FCF	-	EPS past 3/5Y	- -25.87%	ROIC	-3.93%	52W Low	76.53 39.12%	Perf 3Y	-19.52%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-49.00% 89.57%	Gross Margin	79.48%	Volatility	2.17% 3.32%	Perf 5Y	104.54%
Dividend TTM	-	EV/Sales	3.73	EPS Y/Y TTM	-764.64%	Oper. Margin	-23.98%	ATR (14)	3.75	Perf 10Y	-
Dividend Ex-Date	Jun 02, 2022	Quick Ratio	10.02	Sales Y/Y TTM	0.58%	Profit Margin	-27.39%	RSI (14)	53.76	Recom	1.52
Dividend Gr. 3/5Y	- -	Current Ratio	10.18	EPS Q/Q	-28.06%	SMA20	-0.76%	Beta	1.29	Target Price	140.77
Payout	-	Debt/Eq	0.02	Sales Q/Q	-5.51%	SMA50	3.54%	Rel Volume	0.30	Prev Close	106.72
Employees	6772	LT Debt/Eq	0.01	Earnings	May 05 BMO	SMA200	-2.77%	Avg Volume	1.21M	Price	106.47
IPO	Oct 10, 2019	Option/Short	Yes / Yes	EPS/Sales Surpr.	24.28% -9.61%	Trades		Volume	367,468	Change	-0.23%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-05-25	Reiterated	H.C. Wainwright	Buy	$134 → $145
May-29-25	Initiated	Goldman	Neutral	$110
Mar-13-25	Initiated	Citigroup	Buy	$145
Jan-10-25	Initiated	Truist	Buy	$172
Dec-11-24	Initiated	Wells Fargo	Overweight	$170
Dec-02-24	Reiterated	BMO Capital Markets	Outperform
Nov-19-24	Upgrade	Evercore ISI	In-line → Outperform	$110 → $125
Nov-19-24	Initiated	Berenberg	Buy	$130
Nov-08-24	Upgrade	Goldman	Neutral → Buy	$90 → $137
Sep-24-24	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$93 → $145
Sep-17-24	Upgrade	Jefferies	Hold → Buy	$96 → $150
Sep-16-24	Upgrade	JP Morgan	Underweight → Neutral	$91 → $125
Aug-07-24	Upgrade	Deutsche Bank	Hold → Buy	$95
Aug-02-24	Upgrade	HSBC Securities	Hold → Buy
May-14-24	Initiated	Evercore ISI	In-line	$100
Feb-23-24	Initiated	BMO Capital Markets	Outperform	$127
Jan-05-24	Initiated	Oppenheimer	Perform
Dec-01-23	Downgrade	JP Morgan	Neutral → Underweight	$106 → $99
Oct-16-23	Downgrade	HSBC Securities	Buy → Hold	$124 → $111
Jul-14-23	Initiated	HSBC Securities	Buy	$124

Show Previous Ratings

Today 09:50AM	BMY Loses 16.3% YTD: Should You Buy, Sell or Hold the Stock? (Zacks)
Jun-20-25 11:51AM	CureVac Soars 41% in a Month on a $1.25B Buyout Offer From BioNTech (Zacks)
Jun-13-25 12:15PM	Oracle reports Q4 beat, BioNTech to acquire CureVac: Morning Buzz (TipRanks)
08:16AM	BioNTech buys mRNA, courtroom rival CureVac in all-stock deal (BioPharma Dive)
Jun-12-25 12:49PM	BioNTech bolsters mRNA pipeline with $1.25bn CureVac acquisition (Pharmaceutical Technology)
12:11PM	Loading…
12:11PM	Gold prices, BioNTech to acquire CureVac, Tapestry upgrade (Yahoo Finance Video)
10:25AM	COVID-19 Vaccine Maker BioNTech Buys CureVac as It Aims for Cancer Treatments (Investopedia)
10:20AM	BioNTech to Buy CureVac in $1.25 Billion Deal to Boost Its Cancer Business (Barrons.com)
09:15AM	BMY Reports Positive Data on Sotyktu From Arthritis Study (Zacks)
07:51AM	BioNTech to Acquire CureVac in Stock Deal Valued Around $1.25 Billion (The Wall Street Journal)
07:44AM	CureVac stock soars about 30% after BioNTech agrees to acquire co (Investing.com)
07:18AM	Stocks to Watch Thursday: Boeing, Oracle, GameStop, CureVac (The Wall Street Journal)
07:11AM	BioNTech to Buy CureVac in $1.25 Billion Deal. Both Stocks Are Rising. (Barrons.com)
06:58AM	BioNTech takes over CureVac in $1.25 billion all-stock deal among COVID rivals (Reuters)
06:45AM	BioNTech Announces Strategic Transaction to Acquire CureVac in Public Exchange Offer (GlobeNewswire)
10:20AM	Loading…
Jun-11-25 10:20AM	Trump Trade: RFK Jr. removes members of vaccine-advising CDC panel (TipRanks)
Jun-10-25 04:10PM	Vaccine Stocks Mixed After RFK Jr. Fires CDC's Entire Vaccine Committee (Investor's Business Daily)
10:10AM	RFK Jr. removes CDC vaccine panel members: What to know (Yahoo Finance Video)
08:18AM	Why Moderna, Pfizer Stocks Are Shrugging Off RFK Jr.'s Firing of Vaccine Advisors. (Barrons.com)
Jun-09-25 06:07PM	Vaccine Stocks Moderna, Pfizer Hit After A Surprise Blow From RFK Jr. (Investor's Business Daily)
Jun-06-25 09:16AM	BMY Collaborates for Oncology Drug: Will This Boost Its Portfolio? (Zacks)
01:30AM	Despite Trade War, U.S. Drug Companies Turn to China for Key Cancer Treatments (Barrons.com)
Jun-03-25 12:11PM	Bristol Myers Collaborates With BNTX for Oncology Candidate (Zacks)
06:42AM	Trump's Tax Bill Is Testing the Dollar. This Red Flag Matters More. (Barrons.com)
06:30AM	Bristol Myers Paying BioNTech Up to $11.1B in Cancer Drug Team-up (The Daily Upside)
02:22AM	Why BioNTech SE (BNTX) Skyrocketed On Monday (Insider Monkey)
Jun-02-25 06:54PM	Analyst Report: BioNTech SE (Morningstar Research) +18.05%
03:18PM	BioNTech Gains 20% On $11.1 Billion Bristol Deal (GuruFocus.com)
01:38PM	Why BioNTech Stock Soared Today (Motley Fool)
12:15PM	BMS outlays $11bn to join BioNTechs development of bispecific cancer drug (Pharmaceutical Technology)
12:10PM	Loading…
12:10PM	Trump's steel tariffs, Bristol Myers-BioNTech, sports bet tax (Yahoo Finance Video)
11:55AM	Cancer Moonshot: Bristol-Myers Just Dropped $11 Billion on a Single BioNTech Drug (GuruFocus.com)
11:46AM	Summit Therapeutics Stock Nosedives on Mixed NSCLC Study Results (Zacks)
11:45AM	M&A is 'lifeblood' of biopharma: Analyst on Sanofi-Blueprint deal (Yahoo Finance Video)
11:39AM	Bristol Myers Joins Pharma's Hottest Horserace in $11.1B Deal With BioNTech (Barrons.com)
10:16AM	BioNTech Stock Jumps on Bristol Myers Squibb Cancer Drug Collaboration (Investopedia)
10:14AM	Bristol Myers Inks $11 Billion Licensing Pact With BioNTech For Bispecific Cancer Drug (Benzinga)
08:46AM	Bristol Myers makes $11 billion deal with BioNTech to join the cancer-drug race (MarketWatch)
08:42AM	Stocks to Watch Monday: Alphabet, Tesla, UnitedHealth, Steel Dynamics (The Wall Street Journal)
08:07AM	Bristol to Pay BioNTech Up to $11.1 Billion in Cancer Deal (Bloomberg)
08:04AM	BioNTech soars 15% on cancer drug deal with Bristol Myers (Investing.com)
07:42AM	BioNTech Sets Cancer-Drug Deal With Bristol Myers Squibb (The Wall Street Journal)
07:21AM	BioNTech and Bristol Myers Squibb enter up to $11.1B cancer drug collaboration (Investing.com)
06:45AM	BioNTech and Bristol Myers Squibb Announce Global Strategic Partnership to Co-Develop and Co-Commercialize Next-generation Bispecific Antibody Candidate BNT327 Broadly for Multiple Solid Tumor Types (Business Wire)
02:45AM	Bristol Myers allies with BioNTech on bispecific cancer drug (BioPharma Dive)
May-27-25 08:15AM	BioNTech to Present Progress Across Diversified Oncology Pipeline at the 2025 ASCO Annual Meeting (GlobeNewswire)
May-26-25 09:41AM	MRNA Seeks FDA Nod for Updated COVID-19 Vaccine (Zacks)
May-22-25 06:52AM	FDA advisers pan Pfizers PARP drug; Sarepta to resume Duchenne study (BioPharma Dive)
May-21-25 03:26PM	BioNTech Strengthens UK Ties with Investment of Up to $1.33 Billion (Insider Monkey)
11:10AM	FDA to mandate trials for COVID boosters for healthy kids and adults (TipRanks)
08:37AM	MRNA, PFE Stocks Jump Despite FDA's Stricter Standards for COVID-19 Shots (Zacks)
06:37AM	BioNTech to invest up to $1.34bn in UK R&D (Pharmaceutical Technology)
May-20-25 12:22PM	The FDA Is Limiting Covid Shots. But Moderna, Vaccine Stocks Jumped. (Investor's Business Daily)
May-13-25 10:00PM	BioNTech SE (BNTX): Among the Best Growth Stocks to Buy and Hold for the Long Term (Insider Monkey)
May-06-25 07:19PM	Analyst Report: BioNTech SE (Morningstar Research) -6.29%
06:15PM	Why BioNTech Stock Got Trounced on Tuesday (Motley Fool)
03:03AM	BioNTech SE (BNTX) Q1 2025 Earnings Call Highlights: Navigating Challenges and Advancing ... (GuruFocus.com)
01:16AM	Q1 2025 Biontech SE Earnings Call (Thomson Reuters StreetEvents)
May-05-25 05:09PM	Analyst Report: BioNTech SE (Morningstar Research)
11:39AM	BioNTech SE (BNTX) Q1 2025 Earnings Call Transcript (Seeking Alpha)
06:45AM	BioNTech Announces First Quarter 2025 Financial Results and Corporate Update (GlobeNewswire)
06:30AM	BioNTech Announces Appointment of Ramón Zapata to Management Board as Chief Financial Officer (GlobeNewswire)
06:30AM	BioNTech Announces Appointment of Ramon Zapata to Management Board as Chief Financial Officer (GlobeNewswire)
Apr-30-25 07:33AM	Baron Focused Growth Fund Q1 2025 Shareholder Letter (Seeking Alpha)
Apr-29-25 11:34AM	Pfizer Q1 Earnings Beat Estimates, Several Headwinds Hurt Sales (Zacks)
Apr-26-25 12:50PM	Akeso survival data for ivonescimab misses expectations, STAT says (TipRanks)
09:30AM	Summit Therapeutics: New Ivonescimab Data Raise Concerns (Seeking Alpha)
Apr-25-25 05:05PM	Why Biotech Stars Summit Therapeutics and BioNTech Plunged, Even as This Chinese Rival Surged Today (Motley Fool) -15.36%
07:06AM	Will Pfizer's Non-COVID Drugs Drive Sales Again This Earnings Season? (Zacks)
Apr-24-25 06:45AM	BioNTech to Present Clinical and Preclinical Data Across mRNA and Next-Generation Immuno-Oncology Priority Programs at AACR 2025 (GlobeNewswire)
01:48AM	Novavax (NVAX) Surges 19.5%: Is This an Indication of Further Gains? (Zacks)
Apr-23-25 04:10PM	BioNTech Surges On Summit's Coattails. But Can They Take On Merck? (Investor's Business Daily) +9.70%
06:58AM	Pfizer Stock Before Q1 Earnings Release: To Buy or Not to Buy? (Zacks)
Apr-22-25 07:37PM	Analyst Report: BioNTech SE (Morningstar Research)
06:45AM	BioNTech to Report First Quarter 2025 Financial Results and Corporate Update on May 5, 2025 (GlobeNewswire)
Apr-21-25 05:02PM	BioNTech SE (BNTX) Q4 2024 Earnings Call Highlights: Navigating Challenges and Advancing Innovations (GuruFocus.com)
Apr-20-25 11:28AM	IDNA: The Cutting Edge Of Medical Science Is A Risky Investment (Seeking Alpha)
Apr-15-25 09:01AM	Strength Seen in BioNTech (BNTX): Can Its 6.0% Jump Turn into More Strength? (Zacks)
Apr-14-25 09:10AM	Zai Lab Limited (ZLAB) Moves 21.5% Higher: Will This Strength Last? (Zacks) +6.03%
09:08AM	Summit Therapeutics: Multibillion Dollar NSCLC Potential Faces Growing Competition (Seeking Alpha)
05:57AM	Here's Why Summit Therapeutics Stock Soared 15% on Friday (Zacks)
Apr-11-25 08:39AM	Novavax: Regulatory Uncertainty Creates Risk And Opportunity For Beaten-Down Vaccine Developer (Seeking Alpha)
Apr-10-25 09:44AM	Pfizer Stock Falls to New 52-Week Low: Should You Buy the Dip? (Zacks)
Apr-09-25 05:00AM	Barbara Weber, M.D., Elected to ITM Supervisory Board (GlobeNewswire) +8.64%
Apr-02-25 03:37PM	Is BioNTech SE (BNTX) the Best German Stock to Buy According to Hedge Funds? (Insider Monkey)
Mar-31-25 05:15PM	FDA Shake-Up Rocks Moderna Stock As Regulatory Risks Mount (Downgrade) (Seeking Alpha)
09:57AM	Moderna, biotech stocks slide following resignation of FDA official Peter Marks (Yahoo Finance)
Mar-28-25 03:24PM	CureVac: Patent Win Notable, But Won't Answer More Fundamental Questions (Seeking Alpha)
Mar-25-25 05:40PM	Is BioNTech SE (BNTX) a Promising Biotech Stock According to Wall Street Analysts (InsiderMonkey)
Mar-24-25 09:25PM	Barrons 10 Favorite Stocks for 2024 (Barrons.com) +5.51%
Mar-21-25 03:03AM	Autolus Therapeutics PLC (AUTL) Q4 2024 Earnings Call Highlights: Financial Growth Amid Rising Costs (GuruFocus.com)
Mar-20-25 08:02PM	Analyst Report: BioNTech SE (Morningstar Research)
05:49PM	Former Texas congressman Burgess eyed as CDC director nominee - report (SeekingAlpha)
Mar-11-25 01:02AM	Q4 2024 Biontech SE Earnings Call (Thomson Reuters StreetEvents) -6.61%
Mar-10-25 09:21PM	Analyst Report: BioNTech SE (Morningstar Research)
03:15PM	BioNTech Se (BNTX) Q4 2024 Earnings Call Transcript (Motley Fool)
11:48AM	BioNTech Stock Drops as Sales Outlook Disappoints (Investopedia)
06:55AM	BioNTech Announces Fourth Quarter and Full Year 2024 Financial Results and Corporate Update (GlobeNewswire)
Mar-08-25 11:21AM	CDC plans study into potential vaccines, autism connections, Reuters reports (TipRanks)
Mar-07-25 04:04PM	Why Moderna Stock Has Surged 15% This Week Despite Mixed News (Investor's Business Daily)

BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Oezlem Tuereci, and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	SEC Form 4
Jeggle Helmut Wolfgang	Director	Jun 04 '25	Proposed Sale	113.10	150,000	16,965,000	Jun 04 08:31 AM
ATHOS KG	10% Owner	Jun 02 '25	Proposed Sale	110.83	175,000	19,394,800	Jun 02 04:08 PM
ATHOS KG	10% Owner	May 28 '25	Proposed Sale	98.68	500,000	49,340,000	May 28 09:00 AM
Jeggle Helmut Wolfgang	Director	May 07 '25	Proposed Sale	94.74	150,000	14,211,000	May 07 07:30 AM
Richardson Ryan	Officer	Feb 27 '25	Proposed Sale	114.00	26,500	3,021,000	Feb 27 07:57 AM
Medine GmbH	Officer	Feb 20 '25	Proposed Sale	119.58	1,000,000	119,580,000	Feb 20 07:53 AM
Poetting Sierk	Officer	Feb 20 '25	Proposed Sale	119.58	120,000	14,349,600	Feb 20 07:50 AM
ATHOS KG	10% Owner	Dec 13 '24	Proposed Sale	120.69	4,983	601,398	Dec 13 05:56 PM
ATHOS KG	10% Owner	Dec 11 '24	Proposed Sale	116.85	22,450	2,623,283	Dec 11 05:25 PM
ATHOS KG	10% Owner	Dec 09 '24	Proposed Sale	121.72	53,716	6,538,312	Dec 09 06:35 PM
ATHOS KG	10% Owner	Dec 06 '24	Proposed Sale	118.84	13,104	1,557,279	Dec 06 05:57 PM
ATHOS KG	10% Owner	Nov 27 '24	Proposed Sale	118.54	44,374	5,260,094	Nov 27 05:50 PM
ATHOS KG	10% Owner	Nov 26 '24	Proposed Sale	120.76	10,000	1,207,600	Nov 26 06:37 PM
ATHOS KG	10% Owner	Nov 25 '24	Proposed Sale	113.13	75,000	8,484,750	Nov 25 05:06 PM
Jeggle Helmut Wolfgang	Director	Nov 15 '24	Proposed Sale	103.56	150,000	15,534,000	Nov 15 05:12 PM
Tureci Ozlem	Officer	Nov 12 '24	Proposed Sale	108.73	556,000	60,453,880	Nov 12 07:39 AM
ATHOS KG	10% Owner	Oct 16 '24	Proposed Sale	117.74	8,036	946,154	Oct 16 05:03 PM
ATHOS KG	10% Owner	Oct 14 '24	Proposed Sale	120.83	25,424	3,071,964	Oct 15 08:41 AM
ATHOS KG	10% Owner	Oct 11 '24	Proposed Sale	120.13	40,000	4,805,228	Oct 11 04:15 PM
ATHOS KG	10% Owner	Oct 10 '24	Proposed Sale	117.47	20,000	2,349,436	Oct 10 04:13 PM
ATHOS KG	10% Owner	Oct 09 '24	Proposed Sale	119.06	6,000	714,361	Oct 09 04:02 PM
ATHOS KG	10% Owner	Oct 08 '24	Proposed Sale	122.01	15,000	1,830,100	Oct 08 04:24 PM
ATHOS KG	10% Owner	Oct 04 '24	Proposed Sale	122.80	14,756	1,812,078	Oct 04 04:17 PM
ATHOS KG	10% Owner	Oct 03 '24	Proposed Sale	119.27	50,000	5,963,585	Oct 03 05:14 PM
ATHOS KG	10% Owner	Oct 02 '24	Proposed Sale	119.04	65,200	7,761,193	Oct 02 06:18 PM
ATHOS KG	10% Owner	Oct 01 '24	Proposed Sale	119.24	72,086	8,595,657	Oct 01 04:18 PM
ATHOS KG	10% Owner	Sep 30 '24	Proposed Sale	118.22	76,114	8,998,197	Sep 30 04:52 PM
ATHOS KG	10% Owner	Sep 27 '24	Proposed Sale	117.64	37,204	4,376,679	Sep 27 05:12 PM
ATHOS KG	10% Owner	Sep 25 '24	Proposed Sale	118.47	37,943	4,495,107	Sep 25 07:14 PM
ATHOS KG	10% Owner	Sep 18 '24	Proposed Sale	124.71	55,605	6,934,500	Sep 18 07:28 PM
ATHOS KG	10% Owner	Sep 17 '24	Proposed Sale	124.49	30,162	3,754,792	Sep 17 04:14 PM
ATHOS KG	10% Owner	Sep 16 '24	Proposed Sale	123.40	500,000	61,700,000	Sep 16 05:35 PM
ATHOS KG	10% Owner	Sep 16 '24	Proposed Sale	126.02	90,000	11,341,611	Sep 16 04:12 PM
ATHOS KG	10% Owner	Sep 13 '24	Proposed Sale	115.02	170,000	19,552,584	Sep 13 04:12 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

BNTX

BioNTech SE ADR

Upgrade your FINVIZ experience